Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Ten-Year Trends in Attributable and Contributable Mortality of Culture-Positive Invasive Aspergillosis in Patients with Hematologic Malignancies: Have We Reached the “Ceiling Efficacy Effect” of Modern Antifungals?. Local targets link to admitted publications; unresolved targets remain external evidence.
Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes
10.1111/ejh.12565 · 2016 · External reference
The complex case of aspergillus and mortality
10.1093/cid/ciy698 · 2019 · External reference
Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia
10.1016/j.leukres.2014.01.007 · 2014 · External reference
Changes in causes of death over time after treatment for invasive aspergillosis
10.1002/cncr.23441 · 2008 · External reference
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study
10.3324/haematol.2009.012054 · 2010 · External reference
Therapeutic horizon of acute myeloid leukemia: success, optimism, and challenges
10.1002/cncr.35806 · 2025 · External reference
Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
10.1093/cid/ciz1008 · 2020 · External reference
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
10.1056/nejmoa020191 · 2002 · External reference
Clinical characteristics and outcomes of invasive aspergillosis in patients with hematological malignancies and transplantation and cellular therapies in the contemporary era
10.1007/s11046-025-01046-1 · 2026 · External reference
Aspergillosis-attributable mortality in the United States: analysis of death certificate data
10.1093/cid/ciaf653 · 2025 · External reference
Superiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial
10.1093/cid/ciae501 · 2025 · External reference
Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial
10.1093/jac/dkx423 · 2018 · External reference
Factors associated with overall and attributable mortality in invasive aspergillosis
10.1086/592255 · 2008 · External reference
Investigational antifungal agents for invasive mycoses: a clinical perspective
10.1093/cid/ciab1070 · 2022 · External reference
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
10.1016/s0140-6736(15)01159-9 · 2016 · External reference
